Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Genflow Biosciences Plc ( (GB:GENF) ).
Genflow Biosciences Plc announced the successful completion of the dosing phase in their canine gene therapy trial, with no adverse events reported, indicating a strong safety profile. The trial, which began in March 2025, aims to assess the efficacy of their SIRT6-based gene therapy in extending healthspan, with initial results expected in January 2026 and further assessments in mid-2026. The company plans to explore early-stage licensing opportunities with animal health companies based on the efficacy data.
More about Genflow Biosciences Plc
Genflow Biosciences Plc, founded in 2020 and headquartered in the UK with R&D facilities in Belgium, is a biotechnology company focused on developing gene therapies aimed at slowing the aging process. Their lead compound, GF-1002, utilizes a centenarian variant of the SIRT6 gene, showing promising preclinical results. The company is also exploring treatments for Metabolic Dysfunction-Associated Steatohepatitis (MASH), a prevalent chronic liver disease.
Average Trading Volume: 5,678,223
Technical Sentiment Signal: Buy
Current Market Cap: £8.51M
Find detailed analytics on GENF stock on TipRanks’ Stock Analysis page.